Foretinib

DRUG4 trials

Sponsors

GlaxoSmithKline, NCIC Clinical Trials Group

Conditions

Breast CancerCancerCarcinoma, HepatocellularRecurrent Breast Cancer

Phase 1

Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer

CompletedNCT00920192

GlaxoSmithKlineCarcinoma, Hepatocellular

Start: 2009-08-12End: 2015-03-24Updated: 2017-07-18

Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer

CompletedNCT01138384

NCIC Clinical Trials GroupBreast Cancer

Start: 2010-10-27End: 2015-02-13Updated: 2023-08-04

Phase 2

A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer

CompletedNCT01147484

NCIC Clinical Trials GroupRecurrent Breast Cancer

Start: 2010-09-02End: 2015-02-13Updated: 2023-08-04

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

WithdrawnNCT02034097

GlaxoSmithKlineCancer

Start: 2014-04-30End: 2016-12-31Updated: 2014-05-19

Related Papers

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.

2016-04-2638 citations